类鼻疽伯克霍尔德菌
类鼻疽
头孢他啶
抗菌剂
医学
抗生素
磺胺甲恶唑
阿莫西林
重症监护医学
抗生素耐药性
甲氧苄啶
克拉维酸
微生物学
生物
细菌
病理
铜绿假单胞菌
遗传学
出处
期刊:Asian Biomedicine
[De Gruyter]
日期:2014-04-01
卷期号:8 (2): 167-172
标识
DOI:10.5372/1905-7415.0802.276
摘要
Abstract Background: Burkholderia pseudomallei are the causative agent of melioidosis, a potentially life-threatening disease in humans and animals. It is a common public health threat in parts of Thailand. Objective: To summarizes the current knowledge regarding antimicrobial agents and B. pseudomallei. Methods: A literature search using MEDLINE (PubMed), SCOPUS, and OVID/LWWW databases. Results: B. pseudomallei are intrinsically resistant to a wide range of antimicrobial agents including β-lactam antibiotics, aminoglycosides, and macrolides. Antimicrobial therapy for melioidosis is divided into an acute phase and an eradication phase. The current recommendations for the acute phase are parenteral antimicrobial agents for ≥10 days using ceftazidime or a carbapenem. The eradication phase involves oral antimicrobial agents for ≥180 days using trimethoprim-sulfamethoxazole. Amoxicillin-clavulanic acid may be used as an alternative. Ceftazidime revealed rare primary resistance and a high relapse rate. Conclusion: Patients with acute melioidosis usually need intensive care and appropriate antibiotics for the acute and eradication phases. Ceftazidime is remains an effective agent in Thailand. A trend for decreasing susceptibility to antibiotics requires monitoring.
科研通智能强力驱动
Strongly Powered by AbleSci AI